DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Goldman Sachs - 3 Corinne Jenkins - 3 Jenkins - 2 Geron - 1 KOLs - 1 Michael Bloom - 1 WestRock - 1 Wolfe - 1
Top related locs:
U.S Friday's
Top related orgs:
Food - 2 Drug - 2 Geron - 1 FDA - 1 New York Stock Exchange - 1 Oracle - 1 LSEG - 1 Smurfit Kappa - 1

Search resuls for: "Corinne Jenkins"


5 mentions found


☆ Goldman Sachs says this blood cancer treatment stock can gain 70% ahead of planned drug launch
  + stars: | 2023-09-12 | by ( Pia Singh | ) www.cnbc.com   time to read: +2 min
Goldman Sachs thinks late-stage biotech company Geron was due for a correction and now has the potential to surge higher. Analyst Corinne Jenkins upgraded Geron to buy from neutral. The analyst highlighted U.S. Food and Drug Administration acceptance of Geron's new drug application for imetelstat, a treatment for individuals with transfusion-dependent anemia in lower-risk myelodysplastic syndromes, or MDS. Shares of Geron have taken a hit this year with a 27% drop this quarter and 3.3% in year-to-date losses. "Despite the AdCom, the physicians we spoke with see a very high likelihood of imetelstat approval based on the publicly available data," the analyst said.
Persons: Goldman Sachs, Corinne Jenkins, Geron, KOLs, Jenkins, Michael Bloom Organizations: Geron, Food, Drug, FDA Locations: U.S
☆ Stocks making the biggest moves midday: Oracle, WestRock, Apple, Advance Auto Parts and more
  + stars: | 2023-09-12 | by ( Alex Harring | ) www.cnbc.com   time to read: +3 min
Oracle — Shares dipped more than 12% a day after the software company posted disappointing earnings and revenue guidance for its fiscal second quarter. Oracle's revenue, which came in at $12.45 billion, was weaker than the $12.47 billion forecast by analysts. WestRock — The stock rose 4.8% following news that the paper and packaging company will go through with a merger with Smurfit Kappa. The Wall Street firm said shares may be oversold after the company experienced a temporary outage on its payment processor Square. Elsewhere, Morgan Stanley reiterated its overweight call on Exxon, saying the company was a top pick in its category.
Persons: WestRock, Wolfe, Baird, Goldman Sachs, Corinne Jenkins, Morgan Stanley, Yun Li, Samantha Subin, Hakyung Kim, Lisa Kailai Han, Jesse Pound, Pia Singh, Brian Evans Organizations: New York Stock Exchange, Oracle, LSEG, Smurfit Kappa, Apple —, Casey's, FactSet, Health, P Global, BBB, CVS, Bank of America, Goldman, Food, Drug, Exxon Mobil —, U.S, Texas, Exxon Locations: U.S
☆ Goldman upgrades this biotech, sees the shares doubling
  + stars: | 2023-07-24 | by ( Alex Harring | ) www.cnbc.com   time to read: +2 min
It's a good time to buy into beat-down Amylyx Pharmaceuticals as investors could be underestimating one of its trials, according to Goldman Sachs. Analyst Corinne Jenkins upgraded the pharmaceutical stock to buy from neutral and increased her price target by $4 to $49. Her new price target implies shares can surge 117% from Friday's close. But investors have been concerned about the stock because of low expectations going into the phase 3 Phoenix study for Relyvrio. But Jenkins also said the approval would likely be a positive catalyst for the beat-down stock.
Persons: Goldman Sachs, Corinne Jenkins, Jenkins, Lou Gehrig's, — CNBC's Michael Bloom Organizations: Pharmaceuticals, PHOENIX Locations: Friday's, U.S
☆ This under-the-radar stock can surge more than 60% on a possible treatment for immuno-inflammatory diseases, Goldman Sachs says
  + stars: | 2022-12-01 | by ( Sarah Min | ) www.cnbc.com   time to read: +2 min
Shares of Aclaris Therapeutics can surge more than 60% on the back of a possible new treatment for immuno-inflammatory diseases, including rheumatoid arthritis, according to Goldman Sachs. Analyst Corinne Jenkins initiated coverage of Aclaris Therapeutics with a buy rating, saying she expects promising results out of clinical trials for the company's drug called zunsemetinib . The biopharma stock has already outperformed this year, up nearly 5% in 2022, while the S & P 500 declined roughly 14%. The analyst expects that there will be further catalysts for positive upside as the Aclaris unveils further data for zunsemetinib in 2023. "We see this profile as sufficient to garner modest share in these large indications, fostering a sizable peak sales opportunity which we estimate at > $5B across indications," Jenkins wrote.
☆ Goldman Sachs says this little-known biotech stock can double on potentially ‘blockbuster’ revenue
  + stars: | 2022-12-01 | by ( Sarah Min | ) www.cnbc.com   time to read: +2 min
Investors should buy biopharma stock Altimmune as it can double from here depending on the success of a new obesity drug, according to Goldman Sachs. However, the analyst expects that the growing obesity market is not a "zero-sum game" and has niches for new players. "We believe that cardiovascular and lipid benefits conferred by pemvidutide will allow ALT to earn meaningful market share and blockbuster revenues," Jenkins wrote. The analyst expects further studies on the pemvidutide's treatment on other diseases could also help differentiate the drug. Shares of Altimmune are up 8% this year, but the analyst expects they'll advance further.
0 next >>
Total: 5